A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-Center Study to Evaluate the Efficacy and Safety of nemolizumab in Japanese Pediatric Atopic Dermatitis Patients with moderate to severe pruritus

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2020
This article has no abstract
Epistemonikos ID: ee0e56051055ab498a174cacafe855dd52e919d2
First added on: Apr 11, 2025